Abstract
Phantom measurements were performed with a conventional single-head single-photon emission tomography (SPET) camera in order to validate the relevance of the basal ganglia/frontal cortex iodine-123 iodobenzamide (IBZM) uptake ratios measured in patients. Inside a cylindrical phantom (diameter 22 cm), two cylinders with a diameter of 3.3 cm were inserted. The activity concentrations of the cylinders ranged from 6.0 to 22.6 kBq/ml and the cylinder/background activity ratios varied from 1.4 to 3.8. From reconstructed SPET images the cylinder/ background activity ratios were calculated using three different regions of interest (ROIs). A linear relationship between the measured activity ratio and the true activity ratio was obtained. In patient studies, basal ganglia/frontal cortex IBZM uptake ratios determined from the reconstructed slices using attenuation correction prior to reconstruction were 1.30±0.03 in idiopathic Parkinson's disease (n=9), 1.33±0.09 in infantile and juvenile neuronal ceroid lipofuscinosis (n=7) and 1.34±0.05 in narcolepsy (n=8). Patients with Huntington's disease had significantly lower ratios (1.09±0.04, n=5). The corrected basal ganglia/frontal cortex ratios, determined using linear regression, were about 80% higher. The use of dual-window scatter correction increased the measured ratios by about 10%. Although comprehensive correction methods can further improve the resolution in SPET images, the resolution of the SPET system used by us (1.52 cm) will determine what is achievable in basal ganglia D2 receptor imaging.
Article PDF
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.Avoid common mistakes on your manuscript.
References
Kung HF, Alavi A, Chang W, et al. In vivo SPECT imaging of CNS D-2 dopamine receptors: initial studies with iodine-123 IBZM in humans. J Nucl Med 1990; 31: 573–579.
Verhoeff NPLG, Bobeldijk M, Feenstra MGP, et al. In vitro and in vivo D2-dopamine receptor binding with (123I)S(-)iodo-benzamide (123I-IBZM) in rat and human brain. Int J Rad Appl Instrum [B] 1991;18:837–846.
Seibyl JP, Woods SW, Zoghbi SS, et al. Dynamic SPECT imaging of dopamine D2 receptors in human subjects with iodine-123-IBZM. J Nucl Med 1992; 33:1964–1971.
Brücke T, Podreka I, Angelberger P, et al. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab 1991;11: 220–228.
Larsson SA. Gamma camera emission tomography. Acta Radiol 1980; Suppl 363:1–75.
Koral KF, Wang X; Rogers L, Clinthorne NH, Wang X. SPECT Compton-scattering correction by analysis of energy spectry. J Nucl Med 1988; 29:195–202.
Blokland KAK, Reiber HHC, Pauwels EKJ. Quantitative analysis in single photon emission tomography. Eur J Nucl Med 1992;19:47–61.
King MA, Hademenos MA, Glick SJ. A dual-photopeak window method for scatter correction. J Nucl Med 1992; 33:605–612.
Yanch JC, Flower MA, Webb S. Improved quantification of radionuclide uptake using deconvolution and windowed subtraction techniques for scatter compensation in single photon emission computed tomography. Med Phys 1990;17:1011–1022.
Berding G, Gratz KF, Kolbe H, Hundeshagen H. Dopamine D-2 receptor imaging with (1–123) IBZM SPECT: methodological aspects and clinical results [abstract]. Eur J Nucl Med 1992;19:735.
Axelsson B, Kalin B, von Krusenstierna S, Jacobsson H. Comparison of In-111 granulocytes and Tc-99m albumin colloid for bone marrow scintigraphy by the use of quantitative SPECT imaging. Clin Nucl Med 1990;15:473–479.
Valkema R, van der Berg R, Camps JAJ, et al. Precision of dual photon absorptiometry measurements: comparison of three different methods of selection of region of interest. Eur J Nucl Med 1989;15:183–188.
Costa D, George MS, Ell PJ, Verhoeff NPLG, Robertson MM. D2 dopamine receptor studies in patients with Gilles de la Tourette syndrome [abstract]. Eur J Nucl Med 1991;18:563.
Tatsch K, Schwarz J, Oertel WH, Kirsch CM. SPECT imaging of dopamine D2 receptors with 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease. Nucl Med Commun 1991;12: 699–707.
Author information
Authors and Affiliations
Additional information
Paper presented in part at the European Association of Nuclear Medicine Congress, 22–26 August 1992, Lisbon, Portugal
Correspondence to: P. Nikkinen, Division of Nuclear Medicine, Meilahti Hospital, SF-00290 Helsinki, Finland
Rights and permissions
About this article
Cite this article
Nikkinen, P., Liewendahl, K., Savolainen, S. et al. Validation of quantitative brain dopamine D2 receptor imaging with a conventional single-head SPET camera. Eur J Nucl Med 20, 680–683 (1993). https://doi.org/10.1007/BF00181758
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00181758